Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: Results of an international randomized controlled trial
1998 ◽
Vol 28
(3)
◽
pp. 369-374
◽
1995 ◽
Vol 2
(2)
◽
pp. 73-76
◽
1999 ◽
Vol 94
(1)
◽
pp. 164-168
◽